SAFETY RESULTS FROM AVAglio, A PHASE III RANDOMIZED STUDY OF BEVACIZUMAB (BEV) PLUS STANDARD COMBINATION TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM)

被引：0
|
作者：
Saran, Frank [1 ]
Chinot, Olivier L. [2 ]
Henriksson, Roger [3 ,4 ]
Mason, Warren [5 ]
Wick, Wolfgang [6 ]
Nishikawa, Ryo [7 ]
Dahr, Sunita [8 ]
Hilton, Magalie [9 ]
Garcia, Josep [9 ]
Cloughesy, Timothy [10 ]
机构：
[1] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[2] Aix Marseille Univ, CHU Timone, AP HM, Marseille, France
[3] Reg Canc Ctr Stockholm, Stockholm, Sweden
[4] Umea Univ, Umea, Sweden
[5] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada
[6] Univ Med Ctr, Heidelberg, Germany
[7] Saitama Med Univ, Int Med Ctr, Saitama, Japan
[8] Genentech Inc, San Francisco, CA 94080 USA
[9] F Hoffmann La Roche Ltd, Basel, Switzerland
[10] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
NEURO-ONCOLOGY | 2013年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：127 / 128
页数：2
相关论文
共 50 条
  • [1] FINAL EFFICACY AND SAFETY RESULTS FROM AVAglio, A PHASE III TRIAL OF BEVACIZUMAB (BEV) PLUS TEMOZOLOMIDE (TMZ) ANDRADIOTHERAPY (RT) IN NEWLY DIAGNOSED GLIOBLASTOMA
    Chinot, Olivier L.
    Wick, Wolfgang
    Mason, Warren
    Henriksson, Roger
    Saran, Frank
    Nishikawa, Ryo
    Carpentier, Antoine F.
    Khe Hoang-Xuan
    Kavan, Petr
    Cernea, Dana
    Brandes, Alba A.
    Hilton, Magalie
    Kerloeguen, Yannick
    Guijarro, Abajo
    Cloughsey, Timothy
    [J]. NEURO-ONCOLOGY, 2013, 15 : 105 - 106
  • [2] Efficacy and safety of bevacizumab (By) plus standard combination temozolomide (T) and radiotherapy (RT) in newly diagnosed glioblastoma: final results from AVAglio
    Chinot, O.
    Cloughesy, T.
    Henriksson, R.
    Saran, F.
    Mason, W.
    Nishikawa, R.
    Hilton, M.
    Abrey, L.
    Wick, W.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S774 - S775
  • [3] Biomarker (BM) evaluations in the phase III AVAglio study of bevacizumab (Bv) plus standard radiotherapy (RT) and temozolomide (T) for newly diagnosed glioblastoma (GBM)
    Nishikawa, Ryo
    Saran, Frank
    Mason, Warren
    Wick, Wolfgang
    Cloughesy, Timothy Francis
    Henriksson, Roger
    Hilton, Magalie
    Garcia, Josep
    Vogt, Tobias
    Pallaud, Celine
    Chinot, Oliver L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] CORRELATION OF MOLECULAR SUBTYPES WITH OVERALL SURVIVAL (OS) IN AVAGLIO, A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB (BEV) PLUS RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Phillips, Heidi
    Sandmann, Thomas
    Li, Congfen
    Cloughesy, Timothy
    Chinot, Olivier L.
    Wick, Wolfgang
    Nishikawa, Ryo
    Mason, Warren
    Henriksson, Roger
    Saran, Frank
    Lai, Albert
    Moore, Nicola
    Hegde, Priti
    Abrey, Lauren
    Bourgon, Richard
    Garcia, Josep
    Bais, Carlos
    [J]. NEURO-ONCOLOGY, 2014, 16
  • [5] Efficacy and safety of bevacizumab (By) plus standard combination temozolomide (T) and radiotherapy (RI) in newly diagnosed glioblastoma: Final results from AVAglio
    Wick, W.
    Cloughesy, T.
    Henrikkson, R.
    Saran, F.
    Mason, W.
    Nishikawa, R.
    Hilton, M.
    Abrey, L.
    Chinot, O.
    [J]. ONKOLOGIE, 2013, 36 : 94 - 94
  • [6] Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).
    Omuro, A. M. P.
    Beal, K.
    Karimi, S.
    Correa, D.
    Chan, T. A.
    DeAngelis, L. M.
    Gavrilovic, I. T.
    Nolan, C.
    Hormigo, A.
    Lassman, A. B.
    Kaley, T. J.
    Mellinghoff, I. K.
    Grommes, C.
    Panageas, K.
    Reiner, A. S.
    Barradas, R.
    Abrey, L. E.
    Gutin, P. H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Phase II Study of Bevacizumab (BEV), Temozolomide (TMZ) and Hypofractionated Stereotactic Radiotherapy (HFSRT) for Newly Diagnosed Glioblastoma (GBM)
    Beal, K.
    Omuro, A.
    Karimi, S.
    Correa, D.
    Chan, T. A.
    DeAngelis, L. M.
    Yamada, Y.
    Abrey, L. E.
    Gutin, P. H.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S129 - S129
  • [8] Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).
    Omuro, A. A.
    Beal, K.
    Karimi, S.
    Chan, T. A.
    Panageas, K.
    Nayak, L.
    Seko, B.
    DeAngelis, L. M.
    Abrey, L. E.
    Gutin, P. H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Combination of temozolomide (TMZ) and radiotherapy (RT) versus radiotherapy (RT) alone in newly diagnosed glioblastoma multiforme (GBM): A randomized phase II study
    Athanassiou, H
    Synodinou, M
    Maragoudakis, E
    Paraskevaidis, M
    Verigos, C
    Misailidou, D
    Antonadou, D
    Sarris, G
    Beroukas, K
    Karageorgis, P
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S162 - S163
  • [10] SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO DID NOT RECEIVE POST-PROGRESSION THERAPY IN AVAGLIO (BEVACIZUMAB [BEV] PLUS RADIOTHERAPY [RT] AND TEMOZOLOMIDE [TMZ] FOR NEWLY DIAGNOSED GLIOBLASTOMA [GBM])
    Cloughesy, Tim
    Wick, Wolfgang
    Mason, Warren
    Henriksson, Roger
    Saran, Frank
    Nishikawa, Ryo
    Carpentier, Antoine F.
    Hoang-Xuan, Khe
    Kavan, Petr
    Cernea, Dana
    Brandes, Alba A.
    Revil, Cedric
    Abrey, Lauren
    Chinot, Olivier L.
    [J]. NEURO-ONCOLOGY, 2014, 16
12345